Free tool
FAERS Monitor: Infuvite Adult
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021163 or its brand name (Infuvite Adult, Alpha-Tocopherol Acetate, Ascorbic Acid, Biotin, Cholecalciferol, Cyanocobalamin, Dexpanthenol, Folic Acid, Niacinamide, Pyridoxine Hydrochloride, Riboflavin 5'-Phosphate Sodium, Thiamine Hydrochloride, Vitamin A Palmitate, Vitamin K). Reports on generic versions are filed under their own applications.
Reports
141
Serious
51
36% of reports
Hospitalization
11
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- flushing32
- dyspnoea31
- chest discomfort25
- infusion related reaction18
- nausea15
- vomiting14
- dizziness13
- maternal exposure during pregnancy12
- hypersensitivity10
- anaphylactic reaction9
- chest pain8
- feeling abnormal8
- oxygen saturation decreased8
- anxiety7
- cough7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 7 |
| 2019 | 13 |
| 2020 | 10 |
| 2021 | 14 |
| 2022 | 20 |
| 2023 | 18 |
| 2024 | 12 |
| 2025 | 10 |
| 2026 | 14 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,018 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| flushingSignal | 32 | 47.0 | 34.6 | 1,400 |
| infusion related reactionSignal | 18 | 40.5 | 26.3 | 657 |
| chest discomfortSignal | 25 | 36.4 | 25.5 | 830 |
| anaphylactic reactionSignal | 9 | 24.3 | 12.9 | 179 |
| oxygen saturation decreasedSignal | 8 | 21.2 | 10.8 | 135 |
| maternal exposure during pregnancySignal | 12 | 20.1 | 11.7 | 200 |
| dyspnoeaSignal | 31 | 8.2 | 6.0 | 193 |
| hypersensitivitySignal | 10 | 8.0 | 4.4 | 55 |
| chest painSignal | 8 | 6.4 | 3.3 | 32 |
| feeling abnormalSignal | 8 | 5.0 | 2.5 | 22 |
| vomitingSignal | 14 | 4.4 | 2.7 | 35 |
| dizzinessSignal | 13 | 3.9 | 2.3 | 26 |
| coughSignal | 7 | 3.7 | 1.8 | 12 |
| anxietySignal | 7 | 3.7 | 1.8 | 11 |
| nauseaSignal | 15 | 2.8 | 1.8 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.